GLP-1 Drugs Are Becoming More Than Weight Loss Medicine

Just before the new year, the FDA approved tirzepatide, sold as Zepbound, for a condition that has nothing to do with body weight as an endpoint in itself: moderate to severe obstructive sleep apnea in adults with obesity. It is the clearest signal yet that this drug class's story has moved well past the scale.

The December 20, 2024 approval made tirzepatide the first medicine approved specifically for obstructive sleep apnea and obesity together, according to coverage in Pharmacy Times. It joins a growing list of organ-specific benefits this drug class has now demonstrated in dedicated trials, not just inferred from weight loss.

What the sleep apnea trial actually found

The phase 3 SURMOUNT-OSA trial tested tirzepatide at 10 mg or 15 mg doses in 469 adults with obstructive sleep apnea and obesity over 52 weeks. Among participants not using PAP therapy, tirzepatide reduced the apnea-hypopnea index by roughly 25 fewer breathing disruptions per hour compared with about 5 fewer for placebo, described as tirzepatide being approximately five times more effective than placebo at reducing breathing disruptions, according to reporting from NeurologyLive. Among those already using PAP therapy, the reduction was 29 fewer disruptions per hour versus 6 for placebo. Nearly half of treated patients experienced remission or only mild symptoms after a year.

Semaglutide's heart disease approval

Tirzepatide's newest approval follows a related milestone for semaglutide. The SELECT trial, a cardiovascular outcomes study of 17,604 adults with overweight or obesity and established cardiovascular disease but without diabetes, found that semaglutide reduced the composite risk of cardiovascular death, nonfatal heart attack, or nonfatal stroke by 20 percent compared with placebo over a mean follow-up of roughly 40 months, according to results published in The New England Journal of Medicine. That data supported the FDA's approval of Wegovy for cardiovascular risk reduction in adults with known heart disease and overweight or obesity, granted on March 8, 2024.

What SELECT found on kidney outcomes too

SELECT was not designed primarily as a kidney trial, but its long-term kidney outcome data, examined in a dedicated analysis published on PMC, adds to a broader picture of renal benefit associated with semaglutide in people with cardiovascular disease and excess weight, independent of a diabetes diagnosis.

The dedicated kidney trial: FLOW

A separate and more direct test of kidney benefit came from the FLOW trial, which enrolled people with type 2 diabetes and chronic kidney disease specifically. Novo Nordisk stopped the trial early, in October 2023, after an independent monitoring committee found sufficiently strong efficacy signals to warrant halting it ahead of schedule, according to HCPLive's coverage at the time. Full FLOW results, reported by HCPLive, showed semaglutide reduced major kidney disease events by 24 percent and cardiovascular death risk by 29 percent, alongside a slower decline in kidney filtration rate compared with placebo.

What this pattern adds up to

Taken together, sleep apnea remission with tirzepatide, cardiovascular risk reduction and kidney protection with semaglutide, the data suggests these drugs are doing something broader than suppressing appetite. Slowing the metabolic and inflammatory processes tied to obesity appears to ripple outward into organ systems well beyond the pancreas and stomach that the drugs were originally designed to target.

This article reports on published, peer-reviewed trial results and FDA regulatory decisions and is not medical advice. Whether any of these approved indications, cardiovascular risk reduction, kidney protection or sleep apnea treatment, applies to a specific patient depends on their full clinical picture and should be assessed by their own physician.

With cardiovascular, renal and now sleep-related approvals accumulating for this drug class within roughly a year of each other, the more interesting question for 2025 may be which organ system researchers test next, and whether the trend of expanding benefit continues to hold up under scrutiny.